With Added Indication, Amarin Says Vascepa No ‘Fish Oil’ Like Omega-3s
Executive Summary
In Amarin’s “education process” about indication as an add-on to statin therapy to help cut CV risk in high-risk patients, it “will also be emphasizing how Vascepa is different from” Rx drugs fenofibrate and niacin “and omega-3 mixtures,” says CEO John Thero.
You may also be interested in...
Sales Already Growing As Vascepa Secures Cardio Approval
Company forecasts 2020 sales as high as $700m after regulator grants broad label.
Supreme Court Doesn't Bite On Amarin Appeal In Omega-3 Fair Trade Complaint
The court included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider decisions in civil litigation and convictions in criminal cases. However, Amarin still eyes curbing competition from omega-3 supplements.
Amarin CEO: Consumers Have Heard About Omega-3 Heart Benefits 'Too Long'
As Amarin expects jump in Vascepa sales from potential label expansion allowing larger patient group, John Thero notes competitors fail to show broader cardiovascular risk reduction, but consumers still hear omega-3 supplements "might work."